Recently, several studies reported that a loss of function (LOF) mutation in a PBAF-complex gene PBRM1, that is commonly mutated in ccRCC, was associated with better clinical benefit (CB) from ICIs [4,9,10]. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.